EUVIMEDEUVIMED entdecken
Crossref

Crystal structure of the human LAG-3–HLA-DR1–peptide complex

Jan Petersen iD, Carmen Llerena, Bagher Golzarroshan iD, Camilla Faoro iD, Frederic Triebel iD, Jamie Rossjohn iD

Science Immunology · 2024

DOI: 10.1126/sciimmunol.ads5122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Immunology, 2024. Verfasst von Jan Petersen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Infection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University Clayton, Vict…. Hauptthemen laut MEDLINE: Lymphocyte Activation Gene 3 Protein, Antigens, CD, HLA-DR1 Antigen. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 61 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

T cell activity is governed by T cell receptor (TCR) signaling and constrained by immune checkpoint molecules, including programmed cell death protein 1 (PD-1), cytotoxic T lymphocyte–associated antigen 4 (CTLA-4), and lymphocyte activation gene 3 (LAG-3). The basis for how LAG-3 binds to human leukocyte antigen class II molecules (HLA-II) remains unknown. Here, we present the 3.4-angstrom crystal structure of a LAG-3–peptide–HLA-II complex and probe the energetics of the complex interface. Coincident with the HLA-II binding site of the ancestrally related, monomeric CD4 receptor, the LAG-3 homodimer laterally engages two HLA-II molecules via distal D1 domain surfaces, imposing a 38° angular offset. The LAG-3–HLA-II interface is discontinuous and lacks involvement of the D1 extra loop, a binding site for anti–LAG-3 therapeutic monoclonal antibodies. Upon HLA-II binding, intrinsically mobile loops of the LAG-3 molecule become ordered, with contact residues highly conserved across HLA-DR, DQ, and DP allomorphs. Our data provide a structural foundation for development of immunomodulatory approaches targeting LAG-3.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphocyte Activation Gene 3 ProteinAntigens, CDHLA-DR1 AntigenHumansCrystallography, X-RayPeptidesModels, MolecularProtein Binding

Substanzen

Lymphocyte Activation Gene 3 ProteinAntigens, CDLag3 protein, humanHLA-DR1 AntigenPeptides

Autor:innen und Institutionen

  • Infection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University Clayton, Victoria, Australia.
  • Research & Development, Immutep S.A.S, Saint-Aubin, France.
  • Institute of Infection and Immunity, School of Medicine, Cardiff University, Heath Park, Cardiff, UK.

ORCID-Profile: Jan Petersen, Bagher Golzarroshan, Camilla Faoro, Frederic Triebel, Jamie Rossjohn

Zitieren

APA

Petersen, J., Llerena, C., Golzarroshan, B., Faoro, C., Triebel, F., & Rossjohn, J. (2024). Crystal structure of the human LAG-3–HLA-DR1–peptide complex. Science Immunology. https://doi.org/10.1126/sciimmunol.ads5122

Vancouver

Petersen J, Llerena C, Golzarroshan B, Faoro C, Triebel F, Rossjohn J. Crystal structure of the human LAG-3–HLA-DR1–peptide complex. Science Immunology. 2024. doi:10.1126/sciimmunol.ads5122

BibTeX
@article{Petersen2024,
  author = {Petersen, Jan and Llerena, Carmen and Golzarroshan, Bagher and Faoro, Camilla and Triebel, Frederic and Rossjohn, Jamie},
  title = {Crystal structure of the human LAG-3–HLA-DR1–peptide complex},
  journal = {Science Immunology},
  year = {2024},
  doi = {10.1126/sciimmunol.ads5122}
}
Kostenlos starten →